Global Sickle Cell Anemia Drug Market, Price, Dosage & Clinical Pipeline Outlook 2024
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
“Global Sickle Cell Anemia Drug Market, Price, Dosage & Clinical Pipeline Outlook 2024” Report Highlights:
The sickle shaped red blood cell restricts the uniform circulation of blood and oxygen within the circulatory system; sometimes even leading to the clogging of vessels, which can have serious health complications. Inspite of years of research, there is no known cure for sickle cell anemia. Fortunately, it has been observed that a combination of certain therapeutics along with antibiotics and vitamins has an enhanced efficacy in increasing the longevity and survival of patients, thus leading to the emergence of the sickle cell anemia therapeutics market.
Medications like antibiotics, antimetabolites, analgesics, vaccines and folic acids are the key therapeutics that contributes to more than 50% of the global market size followed by blood transfusion. Further, modern therapeutic methods like gene therapy and bone marrow transplant have also entered the segment in recent years, which currently contributes to a significant market size in the developed region of the world due to their exorbitant cost.
Market trends indicate that the entry of gene therapy and bone marrow transplant are bound to enhance the market growth in the coming years due to their high efficacy in treating sickle cell anemia. Research shows that bone marrow transplant can successfully be applied to treat sickle cell anemia completely along with gene therapy, which is also being considered as a potential cell therapy technique of the future. This discovery has garnered immense attention to the sickle cell therapy market segment globally.
It is evident that the growth of the sickle cell therapy market will indirectly impact the growth of other related market such as the immunosuppressant market, vaccine market, antimetabolites market and vitamin and antibiotic market. Among these, the immunosuppressant market is anticipated to show maximum growth in revenue, owing to the growth of the global sickle cell market.
Sickle cell anemia has been found to be a widely prevalent clinical indication in the African subcontinent with annual incidence being much higher than anywhere else in the world. However, when it comes to the market size, North America takes the lead with close to 40% of the global market size, followed by Europe. This is due to the region’s better accessibility to healthcare and infrastructure. Nonetheless, the rapid increase in the population during the forecast period in the Asia-pacific region is bound to make it the burgeoning market of the future.
KuicK Research Report on the “Global Sickle Cell Anemia Drug Market, Price, Dosage & Clinical Pipeline Outlook 2024” provides an insight into the current scenario of the sickle cell market around key regions of the world. The report provides an in depth analysis of the market with respect to market size, trends and latest market dynamics that might impact the future of the sickle cell market. A detailed cost analysis of therapeutics, growing demand for related therapeutics and several key details have been highlighted to gain an effective insight into the future projections and forecast of the lucrative market.
“Global Sickle Cell Anemia Drug Market, Price, Dosage & Clinical Pipeline Outlook 2024” Report Highlights:
- Sickle Cell Disease Market Opportunity More Than US$ 350 Million
- Price, Dosage & Sales Analysis of Key Drugs
- Global Sickle Cell Anemia Drug Clinical Pipeline by Company & Phase
- Global Sickle Cell Anemia Drug Clinical Pipeline: 40 Drugs
- Marketed Sickle Cell Anemia Drugs: 4 Drugs
- Future Aspects of Global Sickle Cell Disease Treatment Market
The sickle shaped red blood cell restricts the uniform circulation of blood and oxygen within the circulatory system; sometimes even leading to the clogging of vessels, which can have serious health complications. Inspite of years of research, there is no known cure for sickle cell anemia. Fortunately, it has been observed that a combination of certain therapeutics along with antibiotics and vitamins has an enhanced efficacy in increasing the longevity and survival of patients, thus leading to the emergence of the sickle cell anemia therapeutics market.
Medications like antibiotics, antimetabolites, analgesics, vaccines and folic acids are the key therapeutics that contributes to more than 50% of the global market size followed by blood transfusion. Further, modern therapeutic methods like gene therapy and bone marrow transplant have also entered the segment in recent years, which currently contributes to a significant market size in the developed region of the world due to their exorbitant cost.
Market trends indicate that the entry of gene therapy and bone marrow transplant are bound to enhance the market growth in the coming years due to their high efficacy in treating sickle cell anemia. Research shows that bone marrow transplant can successfully be applied to treat sickle cell anemia completely along with gene therapy, which is also being considered as a potential cell therapy technique of the future. This discovery has garnered immense attention to the sickle cell therapy market segment globally.
It is evident that the growth of the sickle cell therapy market will indirectly impact the growth of other related market such as the immunosuppressant market, vaccine market, antimetabolites market and vitamin and antibiotic market. Among these, the immunosuppressant market is anticipated to show maximum growth in revenue, owing to the growth of the global sickle cell market.
Sickle cell anemia has been found to be a widely prevalent clinical indication in the African subcontinent with annual incidence being much higher than anywhere else in the world. However, when it comes to the market size, North America takes the lead with close to 40% of the global market size, followed by Europe. This is due to the region’s better accessibility to healthcare and infrastructure. Nonetheless, the rapid increase in the population during the forecast period in the Asia-pacific region is bound to make it the burgeoning market of the future.
KuicK Research Report on the “Global Sickle Cell Anemia Drug Market, Price, Dosage & Clinical Pipeline Outlook 2024” provides an insight into the current scenario of the sickle cell market around key regions of the world. The report provides an in depth analysis of the market with respect to market size, trends and latest market dynamics that might impact the future of the sickle cell market. A detailed cost analysis of therapeutics, growing demand for related therapeutics and several key details have been highlighted to gain an effective insight into the future projections and forecast of the lucrative market.
1. SICKLE CELL ANEMIA – AN INHERITED BLOOD DISORDER
1.1 Introduction
1.1.1 Signs & Symptoms of Sickle Cell Anemia
1.1.2 Types of Sickle Cell Disease
1.2 Antiquity of Sickle Cell Disease
2. GENETICS & DIAGNOSTICS OF SICKLE CELL DISEASE
2.1 Genetic Mutations
2.2 Diagnostic Approaches for Sickle Cell Disease
2.2.1 Blood Test
2.2.2 Prenatal Testing
2.2.3 Newborn Screening
2.3 Cost Analysis of Sickle Cell Disease Diagnosis
3. MANAGEMENT STRATEGIES FOR SICKLE CELL DISEASE TREATMENT – COST ANALYSIS
3.1 Medication Methods
3.2 Transfusion
3.3 Bone Marrow Transplant
4. TOTAL ANNUAL COST FOR PATIENTS WITH SICKLE CELL DISEASE
4.1 Fees for Hospitalization, Emergency Department & Professional Fees
4.2 Annual Fees for the care of an Adult Patient with Sickle Cell Disease
5. ADVANCE RESEARCH FOR TREATMENT OF SICKLE CELL ANEMIA DISEASE
5.1 Introduction
5.2 Umbilical Cord Blood Transplant
5.3 Gene Therapy
6. SICKLE CELL ANEMIA - DRUG & TREATMENT COST ANALYSIS
6.1 Glutamine (Endari)
6.2 Hydroxycarbamide (Droxia, Hydrea)
6.3 Nicosan (Niprisan or Nix-0699)
6.4 Ibuprofen
7. MARKET ANALYSIS OF SICKLE CELL DISEASE
7.1 Introduction
7.2 Sickle Cell Disease Market Size
8. GLOBAL SICKLE CELL ANEMIA DRUG MARKET DYNAMICS
8.1 Favorable Parameters
8.2 Challenges
9. FUTURE ASPECTS OF GLOBAL SICKLE CELL DISEASE TREATMENT MARKET
10. GLOBAL SICKLE CELL ANEMIA DRUG CLINICAL PIPELINE BY COMPANY & PHASE
10.1 Sickle Cell Anemia Drug Clinical Pipeline Overview
10.2 Research
10.3 Preclinical
10.4 Phase-I
10.5 Phase-I/II
10.6 Phase-II
10.7 Phase-III
11. MARKETED SICKLE CELL ANEMIA DRUG CLINICAL INSIGHT
11.1 Glutamine (Endari & NutreStore)
11.2 Hydroxycarbamide (Siklos)
11.3 Hydroxycarbamide (Droxia, Hydrea, Litalir & OncoCarbide)
11.4 Nix 0699 (Hemoxin, Nicosan & Niprisan)
12. COMPETITIVE LANDSCAPE
12.1 BioMarin
12.2 Bluebird Bio Bluebird Bio
12.3 DeuteRx
12.4 Emmaus Medical
12.5 Gamida Cell
12.6 Global Blood Therapeutics
12.7 GlycoMimetics
12.8 Modus Therapeutics
12.9 Pfizer
12.10 Sancilio Pharmaceuticals
12.11 Sangamo Biosciences
1.1 Introduction
1.1.1 Signs & Symptoms of Sickle Cell Anemia
1.1.2 Types of Sickle Cell Disease
1.2 Antiquity of Sickle Cell Disease
2. GENETICS & DIAGNOSTICS OF SICKLE CELL DISEASE
2.1 Genetic Mutations
2.2 Diagnostic Approaches for Sickle Cell Disease
2.2.1 Blood Test
2.2.2 Prenatal Testing
2.2.3 Newborn Screening
2.3 Cost Analysis of Sickle Cell Disease Diagnosis
3. MANAGEMENT STRATEGIES FOR SICKLE CELL DISEASE TREATMENT – COST ANALYSIS
3.1 Medication Methods
3.2 Transfusion
3.3 Bone Marrow Transplant
4. TOTAL ANNUAL COST FOR PATIENTS WITH SICKLE CELL DISEASE
4.1 Fees for Hospitalization, Emergency Department & Professional Fees
4.2 Annual Fees for the care of an Adult Patient with Sickle Cell Disease
5. ADVANCE RESEARCH FOR TREATMENT OF SICKLE CELL ANEMIA DISEASE
5.1 Introduction
5.2 Umbilical Cord Blood Transplant
5.3 Gene Therapy
6. SICKLE CELL ANEMIA - DRUG & TREATMENT COST ANALYSIS
6.1 Glutamine (Endari)
6.2 Hydroxycarbamide (Droxia, Hydrea)
6.3 Nicosan (Niprisan or Nix-0699)
6.4 Ibuprofen
7. MARKET ANALYSIS OF SICKLE CELL DISEASE
7.1 Introduction
7.2 Sickle Cell Disease Market Size
8. GLOBAL SICKLE CELL ANEMIA DRUG MARKET DYNAMICS
8.1 Favorable Parameters
8.2 Challenges
9. FUTURE ASPECTS OF GLOBAL SICKLE CELL DISEASE TREATMENT MARKET
10. GLOBAL SICKLE CELL ANEMIA DRUG CLINICAL PIPELINE BY COMPANY & PHASE
10.1 Sickle Cell Anemia Drug Clinical Pipeline Overview
10.2 Research
10.3 Preclinical
10.4 Phase-I
10.5 Phase-I/II
10.6 Phase-II
10.7 Phase-III
11. MARKETED SICKLE CELL ANEMIA DRUG CLINICAL INSIGHT
11.1 Glutamine (Endari & NutreStore)
11.2 Hydroxycarbamide (Siklos)
11.3 Hydroxycarbamide (Droxia, Hydrea, Litalir & OncoCarbide)
11.4 Nix 0699 (Hemoxin, Nicosan & Niprisan)
12. COMPETITIVE LANDSCAPE
12.1 BioMarin
12.2 Bluebird Bio Bluebird Bio
12.3 DeuteRx
12.4 Emmaus Medical
12.5 Gamida Cell
12.6 Global Blood Therapeutics
12.7 GlycoMimetics
12.8 Modus Therapeutics
12.9 Pfizer
12.10 Sancilio Pharmaceuticals
12.11 Sangamo Biosciences
LIST OF FIGURES
Figure 1-1: Inheritance Pattern of Sickle Cell Anemia from One Generation to Next Generation
Figure 1-2: Historical Development of Sickle Cell Disease & its Therapeutic Approaches
Figure 2-1: Genetic Mutations which Occur at the Transcription & Translational Level
Figure 2-2: Pathophysiology of Sickle Cell Disease
Figure 2-3: Various Diagnostic Methods for Sickle Cell Disease
Figure 2-4: Price Analysis - Sickle Cell Diagnosis Cost with Insurance (US$), 2018
Figure 2-5: Price Analysis - Sickle Cell Diagnosis Cost without Insurance (US$), 2018
Figure 2-6: Price Analysis - CVS & Amniocentesis for Sickle Cell Anemia(US$), 2018
Figure 2-7: Global - Average NIPT Screening Cost by Technique (US$), 2018
Figure 3-1: Several Management Approaches for Sickle Cell Disease
Figure 3-2: Sickle Cell Disease - Treatment Cost Analysis by Medication (US$/Month), 2018
Figure 3-3: Acceptable Outcomes for Sickle Cell Disease Bone Marrow Transplant
Figure 3-4: Allogeneic & Autogenic Bone Marrow Transplant Cost (US$), 2018
Figure 4-1: Consultation Fees for Sickle Cell Disease (US$/Patient), 2018
Figure 4-2: Hospitalization Charges for Sickle Cell Disease (US$/Day), 2018
Figure 4-3: Price Analysis - Emergency Department Cost (US$/Patient), 2018
Figure 4-4: Emergency Department Professional Fees Billed by Severity (US$), 2018
Figure 4-5: Price Analysis - Average Hospital Charges (US$/SCD patient), 2018
Figure 4-6: Annual Cost Analysis for Tests Involved in Sickle Cell (US$/Patient), 2018
Figure 4-7: Expenditure on SCD Patient by Age (US$/Annum), 2018
Figure 5-1: Ongoing Research for the Development of Sickle Cell Disease Treatment
Figure 5-2: Umbilical Cord Blood Transplant Method for Sickle Cell Anemia
Figure 5-3: Cost Analysis - Umbilical Cord Blood Transplant (US$/Patient), 2018
Figure 5-4: Gene Therapy Method for Sickle Cell Disease Treatment
Figure 5-5: Gene Therapy – Estimated Cost of Therapy & Medication (US$/Patient),2018
Figure 6-1: Endari - Dosage by Body Weight (gram/Dose)
Figure 6-2: Endari - Dosage per day by Body Weight (gram/Day)
Figure 6-3: Endari – Packet Consumption (Number) per Dose by Weight
Figure 6-4: Endari - Packets Consumed (Number of Packets/Day)
Figure 6-5: Endari – Price Analysis for 5mg Tablet (US$/Packet), 2018
Figure 6-6: Droxia – Available Concentrations by type (mg/Tablet)
Figure 6-7: Droxia – Dosage Analysis by Weight (mg/kg)
Figure 6-8: Droxia – Price Analysis per 60 Tablet Packet (US$), 2018
Figure 6-9: Nicosan – Recommended Dosage in children & Adult (mg/Day)
Figure 6-10: Patent Approval Year in UK & US
Figure 6-11: Ibuprofen – Availability by concentration (mg & mg/ml)
Figure 6-12: Ibuprofen – Price of 6ml Intravenous Solution Vial (US$), 2018
Figure 6-13: Ibuprofen – Oral Capsule Price Analysis (US$), 2018
Figure 6-14: Ibuprofen – Price Analysis of Oral Suspension (US$), 2018
Figure 6-15: Ibuprofen – Price Analysis of Oral Tablets (US$/Packet), 2018
Figure 7-1: Burden of Rare Diseases in US & Globally (%)
Figure 7-2: Global - Incidence of Sickle Cell Disease (%), 2018
Figure 7-3: Global - Sickle Cell Anemia Childhood Survival Rates by Region (%), 2018
Figure 7-4: Global – Orphan Drugs Market Forecast (US$ Billion), 2016 - 2024
Figure 7-5: Global - Sickle Cell Disease Market Size (%), 2018
Figure 7-6: Global - Blood Disorders Market Size by Type (%), 2018
Figure 8-1: Favorable Growth Factors for the Sickle Cell Disease Treatment
Figure 8-2: Challenges to the Growth of Sickle Cell Disease Treatment
Figure 9-1: Global - Sickle Cell Disease Market Opportunity (US$ Million), 2018 -2024
Figure 10-1: Global - Sickle Cell Anemia Drug Pipeline by Phase (%), 2018 till 2024
Figure 10-2: Global - Sickle Cell Anemia Drug Pipeline by Phase (Number), 2018 till 2024
Figure 10-3: Global – Discontinued Sickle Cell Anemia Drug Pipeline by Phase (%),2018 till 2024
Figure 10-4: Global - Discontinued Sickle Cell Anemia Drug Pipeline by Phase (Number), 2018 till 2024
Figure 1-1: Inheritance Pattern of Sickle Cell Anemia from One Generation to Next Generation
Figure 1-2: Historical Development of Sickle Cell Disease & its Therapeutic Approaches
Figure 2-1: Genetic Mutations which Occur at the Transcription & Translational Level
Figure 2-2: Pathophysiology of Sickle Cell Disease
Figure 2-3: Various Diagnostic Methods for Sickle Cell Disease
Figure 2-4: Price Analysis - Sickle Cell Diagnosis Cost with Insurance (US$), 2018
Figure 2-5: Price Analysis - Sickle Cell Diagnosis Cost without Insurance (US$), 2018
Figure 2-6: Price Analysis - CVS & Amniocentesis for Sickle Cell Anemia(US$), 2018
Figure 2-7: Global - Average NIPT Screening Cost by Technique (US$), 2018
Figure 3-1: Several Management Approaches for Sickle Cell Disease
Figure 3-2: Sickle Cell Disease - Treatment Cost Analysis by Medication (US$/Month), 2018
Figure 3-3: Acceptable Outcomes for Sickle Cell Disease Bone Marrow Transplant
Figure 3-4: Allogeneic & Autogenic Bone Marrow Transplant Cost (US$), 2018
Figure 4-1: Consultation Fees for Sickle Cell Disease (US$/Patient), 2018
Figure 4-2: Hospitalization Charges for Sickle Cell Disease (US$/Day), 2018
Figure 4-3: Price Analysis - Emergency Department Cost (US$/Patient), 2018
Figure 4-4: Emergency Department Professional Fees Billed by Severity (US$), 2018
Figure 4-5: Price Analysis - Average Hospital Charges (US$/SCD patient), 2018
Figure 4-6: Annual Cost Analysis for Tests Involved in Sickle Cell (US$/Patient), 2018
Figure 4-7: Expenditure on SCD Patient by Age (US$/Annum), 2018
Figure 5-1: Ongoing Research for the Development of Sickle Cell Disease Treatment
Figure 5-2: Umbilical Cord Blood Transplant Method for Sickle Cell Anemia
Figure 5-3: Cost Analysis - Umbilical Cord Blood Transplant (US$/Patient), 2018
Figure 5-4: Gene Therapy Method for Sickle Cell Disease Treatment
Figure 5-5: Gene Therapy – Estimated Cost of Therapy & Medication (US$/Patient),2018
Figure 6-1: Endari - Dosage by Body Weight (gram/Dose)
Figure 6-2: Endari - Dosage per day by Body Weight (gram/Day)
Figure 6-3: Endari – Packet Consumption (Number) per Dose by Weight
Figure 6-4: Endari - Packets Consumed (Number of Packets/Day)
Figure 6-5: Endari – Price Analysis for 5mg Tablet (US$/Packet), 2018
Figure 6-6: Droxia – Available Concentrations by type (mg/Tablet)
Figure 6-7: Droxia – Dosage Analysis by Weight (mg/kg)
Figure 6-8: Droxia – Price Analysis per 60 Tablet Packet (US$), 2018
Figure 6-9: Nicosan – Recommended Dosage in children & Adult (mg/Day)
Figure 6-10: Patent Approval Year in UK & US
Figure 6-11: Ibuprofen – Availability by concentration (mg & mg/ml)
Figure 6-12: Ibuprofen – Price of 6ml Intravenous Solution Vial (US$), 2018
Figure 6-13: Ibuprofen – Oral Capsule Price Analysis (US$), 2018
Figure 6-14: Ibuprofen – Price Analysis of Oral Suspension (US$), 2018
Figure 6-15: Ibuprofen – Price Analysis of Oral Tablets (US$/Packet), 2018
Figure 7-1: Burden of Rare Diseases in US & Globally (%)
Figure 7-2: Global - Incidence of Sickle Cell Disease (%), 2018
Figure 7-3: Global - Sickle Cell Anemia Childhood Survival Rates by Region (%), 2018
Figure 7-4: Global – Orphan Drugs Market Forecast (US$ Billion), 2016 - 2024
Figure 7-5: Global - Sickle Cell Disease Market Size (%), 2018
Figure 7-6: Global - Blood Disorders Market Size by Type (%), 2018
Figure 8-1: Favorable Growth Factors for the Sickle Cell Disease Treatment
Figure 8-2: Challenges to the Growth of Sickle Cell Disease Treatment
Figure 9-1: Global - Sickle Cell Disease Market Opportunity (US$ Million), 2018 -2024
Figure 10-1: Global - Sickle Cell Anemia Drug Pipeline by Phase (%), 2018 till 2024
Figure 10-2: Global - Sickle Cell Anemia Drug Pipeline by Phase (Number), 2018 till 2024
Figure 10-3: Global – Discontinued Sickle Cell Anemia Drug Pipeline by Phase (%),2018 till 2024
Figure 10-4: Global - Discontinued Sickle Cell Anemia Drug Pipeline by Phase (Number), 2018 till 2024
LIST OF TABLES
Table 3-1: Clinical Trials Addressing Transfusion Indications for Sickle Cell Disease
Table 5-2: Droxia – Dosage Analysis by Weight (mg/kg)
Table 3-1: Clinical Trials Addressing Transfusion Indications for Sickle Cell Disease
Table 5-2: Droxia – Dosage Analysis by Weight (mg/kg)
